SG10201913797YA - Methods and compositions for generating or maintaining pluripotent cells - Google Patents
Methods and compositions for generating or maintaining pluripotent cellsInfo
- Publication number
- SG10201913797YA SG10201913797YA SG10201913797YA SG10201913797YA SG10201913797YA SG 10201913797Y A SG10201913797Y A SG 10201913797YA SG 10201913797Y A SG10201913797Y A SG 10201913797YA SG 10201913797Y A SG10201913797Y A SG 10201913797YA SG 10201913797Y A SG10201913797Y A SG 10201913797YA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- generating
- methods
- pluripotent cells
- maintaining pluripotent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462064384P | 2014-10-15 | 2014-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913797YA true SG10201913797YA (en) | 2020-03-30 |
Family
ID=54361190
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702309RA SG11201702309RA (en) | 2014-10-15 | 2015-10-15 | Methods and compositions for generating or maintaining pluripotent cells |
| SG10201913797YA SG10201913797YA (en) | 2014-10-15 | 2015-10-15 | Methods and compositions for generating or maintaining pluripotent cells |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702309RA SG11201702309RA (en) | 2014-10-15 | 2015-10-15 | Methods and compositions for generating or maintaining pluripotent cells |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10428310B2 (es) |
| EP (2) | EP3561052A1 (es) |
| JP (1) | JP2017536811A (es) |
| KR (1) | KR20170070136A (es) |
| CN (1) | CN107002042A (es) |
| AU (1) | AU2015332451A1 (es) |
| BR (1) | BR112017007770A2 (es) |
| CA (1) | CA2963315A1 (es) |
| CY (1) | CY1122179T1 (es) |
| DK (1) | DK3207124T3 (es) |
| ES (1) | ES2741387T3 (es) |
| IL (1) | IL251576A0 (es) |
| MX (1) | MX2017004890A (es) |
| PL (1) | PL3207124T3 (es) |
| PT (1) | PT3207124T (es) |
| RU (1) | RU2706965C2 (es) |
| SG (2) | SG11201702309RA (es) |
| WO (1) | WO2016061374A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013528062A (ja) | 2010-06-11 | 2013-07-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｘｙｅｓ細胞からの繁殖可能なｘｙ雌動物の生成 |
| EP3613852A3 (en) | 2011-07-22 | 2020-04-22 | President and Fellows of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| EP2746386A1 (en) * | 2012-12-21 | 2014-06-25 | Lonza Cologne GmbH | Materials and methods for cell culture |
| LT3456831T (lt) | 2013-04-16 | 2021-09-10 | Regeneron Pharmaceuticals, Inc. | Tikslinis žiurkės genomo modifikavimas |
| US10738323B2 (en) | 2013-07-12 | 2020-08-11 | Cedars-Sinai Medical Center | Generation of induced pluripotent stem cells from normal human mammary epithelial cells |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
| ES2784754T3 (es) | 2014-06-06 | 2020-09-30 | Regeneron Pharma | Métodos y composiciones para modificar un locus objetivo |
| SI3161128T1 (sl) | 2014-06-26 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| EP3561052A1 (en) | 2014-10-15 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
| RS58893B1 (sr) | 2014-11-21 | 2019-08-30 | Regeneron Pharma | Postupci i kompozicije za ciljanu genetičku modifikaciju korišćenjem parnih vodećih rnk |
| CN107429261A (zh) | 2014-12-15 | 2017-12-01 | 应用干细胞有限公司 | 在细胞中迅速产生单一或多重报告基因的方法和组合物 |
| CN107208113A (zh) | 2014-12-19 | 2017-09-26 | 瑞泽恩制药公司 | 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物 |
| AU2016324305B2 (en) | 2015-09-17 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Selection of pluripotent cells for production of fertile XY female mice |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| CA3022319A1 (en) * | 2016-05-06 | 2017-11-09 | Tod M. Woolf | Improved methods for genome editing with and without programmable nucleases |
| US10221395B2 (en) | 2016-06-16 | 2019-03-05 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
| US11572545B2 (en) | 2016-06-16 | 2023-02-07 | Cedars-Sinai Medical Center | Efficient method for reprogramming blood to induced pluripotent stem cells |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| WO2018057782A1 (en) * | 2016-09-23 | 2018-03-29 | University Of Utah Research Foundation | Methods of preventing stem cell differentiation using a pask inhibitor |
| WO2018071868A1 (en) | 2016-10-14 | 2018-04-19 | President And Fellows Of Harvard College | Aav delivery of nucleobase editors |
| JP2018082639A (ja) * | 2016-11-21 | 2018-05-31 | 学校法人千葉工業大学 | 体細胞から人工多能性幹細胞を製造する方法及び人工多能性幹細胞を未分化のまま培養するための培地 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
| US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| CN108552156A (zh) * | 2017-11-13 | 2018-09-21 | 广东艾时代生物科技有限责任公司 | 一种无血清的诱导多功能干细胞冻存液及冻存方法 |
| MX2021011426A (es) | 2019-03-19 | 2022-03-11 | Broad Inst Inc | Metodos y composiciones para editar secuencias de nucleótidos. |
| EP4092104A4 (en) * | 2020-01-14 | 2024-03-06 | Ajinomoto Kk | MEDIUM WITH REDUCED OSMOTIC PRESSURE |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| WO2024020587A2 (en) | 2022-07-22 | 2024-01-25 | Tome Biosciences, Inc. | Pleiopluripotent stem cell programmable gene insertion |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JP2004537260A (ja) | 2000-12-07 | 2004-12-16 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ジンクフィンガータンパク質による血管新生の調節 |
| WO2002057308A2 (en) | 2001-01-22 | 2002-07-25 | Sangamo Biosciences, Inc. | Zinc finger polypeptides and their use |
| CA2435394C (en) | 2001-01-22 | 2018-01-09 | Sangamo Biosciences, Inc. | Modified zinc finger binding proteins |
| US8106255B2 (en) | 2002-01-23 | 2012-01-31 | Dana Carroll | Targeted chromosomal mutagenasis using zinc finger nucleases |
| CN1649489A (zh) | 2002-02-27 | 2005-08-03 | 长尾恭光 | 一种制备种系嵌合动物的方法 |
| US8206965B2 (en) | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| AU2003218382B2 (en) | 2002-03-21 | 2007-12-13 | Sangamo Therapeutics, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| AU2003298574B2 (en) | 2002-09-05 | 2008-04-24 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| AU2003290518A1 (en) | 2002-09-06 | 2004-04-23 | Fred Hutchinson Cancer Research Center | Methods and compositions concerning designed highly-specific nucleic acid binding proteins |
| US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1516924A1 (en) | 2003-09-17 | 2005-03-23 | Fundacion IVI para el Estudio de la reproduccion Humana (FIVIER) | Generation of human embryonic stem cells from triploid zygotes |
| SG150567A1 (en) | 2004-03-23 | 2009-03-30 | Akaike Toshihiro | Pluripotent stem cell growing method |
| EP1591521A1 (en) | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
| AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| CA2827654C (en) | 2004-10-19 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| FR2879622B1 (fr) | 2004-12-17 | 2008-02-01 | Agronomique Inst Nat Rech | Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee |
| WO2006097784A1 (en) | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
| ATE466933T1 (de) | 2005-03-15 | 2010-05-15 | Cellectis | I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung |
| EP1999249B8 (en) * | 2006-03-30 | 2012-02-15 | The University Court Of The University of Edinburgh | Culture medium containing kinase inhibitors. and uses thereof |
| CA2638774C (en) | 2006-03-31 | 2015-11-24 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| GB0623635D0 (en) | 2006-11-27 | 2007-01-03 | Stem Cell Sciences Uk Ltd | Pluripotent cell growth media |
| WO2008076290A2 (en) | 2006-12-14 | 2008-06-26 | Dow Agrosciences Llc | Optimized non-canonical zinc finger proteins |
| US10155038B2 (en) | 2007-02-02 | 2018-12-18 | Yale University | Cells prepared by transient transfection and methods of use thereof |
| WO2008133938A2 (en) | 2007-04-26 | 2008-11-06 | Sangamo Biosciences, Inc. | Targeted integration into the ppp1r12c locus |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| US20110239315A1 (en) | 2009-01-12 | 2011-09-29 | Ulla Bonas | Modular dna-binding domains and methods of use |
| JP5932632B2 (ja) | 2009-03-20 | 2016-06-15 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 改変された亜鉛フィンガータンパク質を使用したｃｘｃｒ４の修飾 |
| US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
| US20120178647A1 (en) | 2009-08-03 | 2012-07-12 | The General Hospital Corporation | Engineering of zinc finger arrays by context-dependent assembly |
| US10913929B2 (en) * | 2009-10-13 | 2021-02-09 | Stemcell Technologies Inc. | Method of differentiating stem cells |
| WO2011059799A1 (en) | 2009-10-29 | 2011-05-19 | Regeneron Pharmaceuticals, Inc. | Multifunctional alleles |
| PL2510096T5 (pl) | 2009-12-10 | 2018-06-29 | Regents Of The University Of Minnesota | Modyfikacja DNA zależna od efektora TAL |
| DK2813572T3 (en) | 2009-12-21 | 2016-08-01 | Keygene Nv | Improved techniques for transfection of protoplasts |
| JP2013528062A (ja) * | 2010-06-11 | 2013-07-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｘｙｅｓ細胞からの繁殖可能なｘｙ雌動物の生成 |
| WO2012129198A1 (en) | 2011-03-23 | 2012-09-27 | Transposagen Biopharmaceuticals, Inc. | Genetically modified rat models for obesity and diabetes |
| CN102851314A (zh) * | 2011-07-01 | 2013-01-02 | 中国科学院上海药物研究所 | 诱导性多能干细胞的制备方法和用于制备诱导性多能干细胞的培养基 |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| SG10201702445TA (en) | 2012-04-25 | 2017-04-27 | Regeneron Pharma | Nuclease-mediated targeting with large targeting vectors |
| RU2650819C2 (ru) | 2012-05-07 | 2018-04-17 | Сангамо Терапьютикс, Инк. | Способы и композиции для опосредованной нуклеазой направленной интеграции трансгенов |
| EA038924B1 (ru) | 2012-05-25 | 2021-11-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Способы и композиции рнк-специфической модификации днк-мишени и рнк-специфической модуляции транскрипции |
| CN105441440B (zh) | 2012-10-23 | 2020-12-15 | 基因工具股份有限公司 | 包含特异于靶dna的向导rna和cas蛋白质编码核酸或cas蛋白质的用于切割靶dna的组合物及其用途 |
| KR102531576B1 (ko) | 2012-12-06 | 2023-05-11 | 시그마-알드리치 컴퍼니., 엘엘씨 | Crispr-기초된 유전체 변형과 조절 |
| ES2883590T3 (es) | 2012-12-12 | 2021-12-09 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| RU2766685C2 (ru) | 2012-12-17 | 2022-03-15 | Президент Энд Фэллоуз Оф Харвард Коллидж | Рнк-направляемая инженерия генома человека |
| WO2014131833A1 (en) | 2013-02-27 | 2014-09-04 | Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) | Gene editing in the oocyte by cas9 nucleases |
| LT3456831T (lt) | 2013-04-16 | 2021-09-10 | Regeneron Pharmaceuticals, Inc. | Tikslinis žiurkės genomo modifikavimas |
| US10920192B2 (en) | 2013-04-23 | 2021-02-16 | Yeda Research And Development Co. Ltd. | Isolated naive pluripotent stem cells and methods of generating same |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| RU2725502C2 (ru) | 2013-06-17 | 2020-07-02 | Те Брод Инститьют Инк. | Доставка, конструирование и оптимизация систем, способы и композиции для целенаправленного воздействия и моделирования заболеваний и нарушений постмитотических клеток |
| CA2915834A1 (en) | 2013-06-17 | 2014-12-24 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| CN105492611A (zh) | 2013-06-17 | 2016-04-13 | 布罗德研究所有限公司 | 用于序列操纵的优化的crispr-cas双切口酶系统、方法以及组合物 |
| CN105793425B (zh) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
| RU2716420C2 (ru) | 2013-06-17 | 2020-03-11 | Те Брод Инститьют Инк. | Доставка и применение систем crispr-cas, векторов и композиций для целенаправленного воздействия и терапии в печени |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| EA037850B1 (ru) | 2013-08-29 | 2021-05-27 | Тэмпл Юниверсити Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн | Способы и композиции для рнк-направленного лечения вич-инфекции |
| WO2015068785A1 (ja) | 2013-11-06 | 2015-05-14 | 国立大学法人広島大学 | 核酸挿入用ベクター |
| DK3066201T3 (en) | 2013-11-07 | 2018-06-06 | Editas Medicine Inc | CRISPR-RELATED PROCEDURES AND COMPOSITIONS WITH LEADING GRADES |
| US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| US10370680B2 (en) | 2014-02-24 | 2019-08-06 | Sangamo Therapeutics, Inc. | Method of treating factor IX deficiency using nuclease-mediated targeted integration |
| KR101823661B1 (ko) | 2014-04-24 | 2018-01-30 | 기초과학연구원 | 마이크로 상동 기반의 유전자 녹아웃을 위한 뉴클레아제 표적 서열을 확인하는 방법 |
| ES2784754T3 (es) | 2014-06-06 | 2020-09-30 | Regeneron Pharma | Métodos y composiciones para modificar un locus objetivo |
| SI3161128T1 (sl) | 2014-06-26 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe |
| MA40253A (fr) | 2014-07-15 | 2017-05-24 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| EP3561052A1 (en) | 2014-10-15 | 2019-10-30 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
| WO2016065364A1 (en) | 2014-10-24 | 2016-04-28 | Life Technologies Corporation | Compositions and methods for enhancing homologous recombination |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| RS58893B1 (sr) | 2014-11-21 | 2019-08-30 | Regeneron Pharma | Postupci i kompozicije za ciljanu genetičku modifikaciju korišćenjem parnih vodećih rnk |
| EP3230452A1 (en) | 2014-12-12 | 2017-10-18 | The Broad Institute Inc. | Dead guides for crispr transcription factors |
| WO2016094874A1 (en) | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Escorted and functionalized guides for crispr-cas systems |
| CN107208113A (zh) | 2014-12-19 | 2017-09-26 | 瑞泽恩制药公司 | 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物 |
| WO2016112351A1 (en) | 2015-01-09 | 2016-07-14 | Bio-Rad Laboratories, Inc. | Detection of genome editing |
| GB201504223D0 (en) | 2015-03-12 | 2015-04-29 | Genome Res Ltd | Biallelic genetic modification |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
-
2015
- 2015-10-15 EP EP19178485.9A patent/EP3561052A1/en not_active Withdrawn
- 2015-10-15 KR KR1020177012730A patent/KR20170070136A/ko unknown
- 2015-10-15 WO PCT/US2015/055776 patent/WO2016061374A1/en active Application Filing
- 2015-10-15 ES ES15787382T patent/ES2741387T3/es active Active
- 2015-10-15 AU AU2015332451A patent/AU2015332451A1/en not_active Abandoned
- 2015-10-15 CN CN201580056328.8A patent/CN107002042A/zh active Pending
- 2015-10-15 SG SG11201702309RA patent/SG11201702309RA/en unknown
- 2015-10-15 DK DK15787382.9T patent/DK3207124T3/da active
- 2015-10-15 BR BR112017007770A patent/BR112017007770A2/pt not_active Application Discontinuation
- 2015-10-15 EP EP15787382.9A patent/EP3207124B1/en active Active
- 2015-10-15 JP JP2017520466A patent/JP2017536811A/ja active Pending
- 2015-10-15 SG SG10201913797YA patent/SG10201913797YA/en unknown
- 2015-10-15 PL PL15787382T patent/PL3207124T3/pl unknown
- 2015-10-15 CA CA2963315A patent/CA2963315A1/en not_active Abandoned
- 2015-10-15 PT PT15787382T patent/PT3207124T/pt unknown
- 2015-10-15 MX MX2017004890A patent/MX2017004890A/es unknown
- 2015-10-15 RU RU2017116678A patent/RU2706965C2/ru active
- 2015-10-15 US US14/884,293 patent/US10428310B2/en active Active
-
2017
- 2017-04-05 IL IL251576A patent/IL251576A0/en unknown
-
2019
- 2019-07-30 CY CY20191100817T patent/CY1122179T1/el unknown
- 2019-08-05 US US16/531,901 patent/US20190382730A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201702309RA (en) | 2017-04-27 |
| US10428310B2 (en) | 2019-10-01 |
| WO2016061374A1 (en) | 2016-04-21 |
| JP2017536811A (ja) | 2017-12-14 |
| DK3207124T3 (da) | 2019-08-12 |
| AU2015332451A1 (en) | 2017-04-20 |
| EP3207124A1 (en) | 2017-08-23 |
| EP3207124B1 (en) | 2019-06-26 |
| CN107002042A (zh) | 2017-08-01 |
| BR112017007770A2 (pt) | 2018-01-16 |
| RU2017116678A (ru) | 2018-11-22 |
| RU2706965C2 (ru) | 2019-11-21 |
| CA2963315A1 (en) | 2016-04-21 |
| ES2741387T3 (es) | 2020-02-10 |
| MX2017004890A (es) | 2018-02-12 |
| IL251576A0 (en) | 2017-06-29 |
| PT3207124T (pt) | 2019-08-27 |
| US20190382730A1 (en) | 2019-12-19 |
| US20160108369A1 (en) | 2016-04-21 |
| PL3207124T3 (pl) | 2019-11-29 |
| EP3561052A1 (en) | 2019-10-30 |
| RU2017116678A3 (es) | 2019-05-22 |
| KR20170070136A (ko) | 2017-06-21 |
| CY1122179T1 (el) | 2020-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL251576A0 (en) | Methods and compositions for creating or maintaining multifunctional cells | |
| HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
| HK1244826A1 (zh) | 用於過繼細胞治療的方法和組合物 | |
| HK1244841A1 (zh) | 用於選擇性消除所關注細胞的方法和組合物 | |
| HK1245080A1 (zh) | 自然殺傷細胞的方法和組合物 | |
| HRP20192145T1 (hr) | Pripravci nosača-antitijela i metode pripreme i uporabe istih | |
| GB2535253B (en) | Compositions and methods | |
| IL271659A (en) | Compositions and methods for modulating expression of complement factor B | |
| GB201709599D0 (en) | Methods for generation of podocytes from pluripotent stem cells and cells produced by the same | |
| IL246879B (en) | Preparations of Epilimod and methods of using them | |
| GB201417828D0 (en) | New methods and compositions | |
| EP3383182C0 (en) | METHODS FOR PRODUCING FUNCTIONAL HEMATOPOIETIC STEM CELLS | |
| RS62981B1 (sr) | Kompozicije i postupci za stimulaciju matičnih ćelija | |
| SG11201702475VA (en) | Methods and compositions for modulating th-gm cell function | |
| PT3113774T (pt) | Composições de grapiprant e métodos de utilização das mesmas | |
| GB201401373D0 (en) | Compositions for cells lysis and uses thereof | |
| GB201402915D0 (en) | Compositions and methods | |
| GB201403212D0 (en) | Compositions and methods |